ESMO E-Learning: Clinical Cases in Colorectal Cancer: Adherence to the ESMO Clinical Practice Guidelines
- To understand factors such as tumour characteristics, patient’s condition and comorbidities, and patient preferences and their importance for decision making in the adjuvant treatment of patients with colon cancer
- To discuss strengths, limitations, and clinical implications of data from trials of adjuvant treatment for colon cancer in the context of evidence-based medicine and emergent clinical practice guidelines
- To discuss the use of adjuvant chemotherapy in colon cancer, as well as the data supporting movement towards a more personalised patient-specific and tumour-specific approach to treating primary colon cancer
|Title||Duration||Content||CME Points||CME Test|
|Clinical Cases in Colorectal Cancer: Adherence to the ESMO Clinical Practice Guidelines||21 min.||22 slides||1||Take Test|
This presentation is developed with the intention of discussing the clinical perspective of the ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of primary colon cancer. The module consists of two specific patient cases with descriptions of the clinical scenario and subsequent discussion about options for adjuvant treatment.
Adjuvant therapy is a systemic treatment administered after primary tumour resection with the aim of reducing the risk of relapse and death. Every treatment option, including observation alone, needs to be discussed with patients according to their characteristics and tumour features. In colon cancer adjuvant treatment is recommended for stage III and patients with high risk stage II. The first issue is therefore how to define the risk. Another important problem is tailoring the decision to each individual patient. Major differences in prognosis depend on factors discussed in the guidelines and this presentation discusses who should be treated and by what methods.
The E-Learning module is composed of two clinical scenarios. The first one is about a 75 year old patient with stage IIIB disease. The challenging question posed regards the initiation of the adjuvant treatment 10, 5 weeks after colon cancer resection due to the postoperative complications. The second case discusses the adjuvant treatment decision in a patient with stage II disease and intermediate risk.
Major differences in prognosis are dependent upon the stage subset, tumour grading, and other biological characteristics. Aiming to enhance experience with the ESMO Clinical Practice Guidelines material, we strongly recommend that oncology professionals refer to the full version of the guidelines text available in the Supplement of Annals of Oncology, as well as the Clinical Practice Guidelines section of the ESMO website.
Prof. Arnold has reported to be a member of the speaker’s bureau of Roche, Amgen, Sanofi and Merck; to be a member of the advisory committees of Amgen, Sanofi, Roche and Merck and a consultant for Bayer Healthcare Pharmaceuticals. He has received research grants from Roche.